LOVENOX
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $19,125 | 6 | 4 |
| 2022 | $51,630 | 11 | 4 |
| 2021 | $50,834 | 15 | 6 |
| 2020 | $6,767 | 4 | 2 |
| 2019 | $7,546 | 9 | 1 |
| 2018 | $2,917 | 5 | 1 |
| 2017 | $18,827 | 4 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $92,266 | 22 | 58.5% |
| Consulting Fee | $36,919 | 8 | 23.4% |
| Travel and Lodging | $17,876 | 7 | 11.3% |
| Unspecified | $10,463 | 14 | 6.6% |
| Food and Beverage | $121.60 | 3 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Effectiveness and Costs of LOVENOX? for Preventing Ischemic Complications among Patients with Unstable Angina and non-ST-segment elevation Myocardial Infarction in the United States | GENZYME CORPORATION | $4,821 | 1 |
| Utilization, effectiveness, and costs of Lovenox and UFH for VTE prophylaxis among medically ill and abdominal surgery patients | GENZYME CORPORATION | $3,503 | 1 |
| Effectiveness and Costs of LOVENOX for Preventing Ischemic Complications among Patients with Unstable Angina and non-ST-segment elevation Myocardial Infarction in the United States | GENZYME CORPORATION | $1,713 | 1 |
| Effectiveness and Costs of LOVENOX? for Preventing Ischemic Complications among Patients with Unstable Angina and non-ST-segment elevation Myocardial Infarction ,in the United States , | GENZYME CORPORATION | $426.12 | 1 |
Top Doctors Receiving Payments for LOVENOX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Surgery | Glenview, IL | $61,385 | 13 |
| , MD | Hematology | Boston, MA | $33,628 | 8 |
| , MD | Hematology & Oncology | New York, NY | $14,891 | 6 |
| , M.D | Hematology & Oncology | Cleveland, OH | $13,748 | 4 |
| , M.D | Cardiovascular Disease | Durham, NC | $13,734 | 17 |
| , MD | Cardiovascular Disease | Cincinnati, OH | $8,160 | 1 |
| , M.D | Internal Medicine | Ann Arbor, MI | $5,609 | 2 |
| , MD | Vascular Surgery | Raleigh, NC | $3,584 | 1 |
| , MD | Surgery | Montgomery, OH | $2,848 | 1 |
| , D.P.M | Foot & Ankle Surgery | Farmington Hills, MI | $58.36 | 1 |
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $143,912
- GENZYME CORPORATION $13,734
Product Information
- Type Drug
- Total Payments $157,646
- Total Doctors 10
- Transactions 54
About LOVENOX
LOVENOX is a drug associated with $157,646 in payments to 10 healthcare providers, recorded across 54 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2017 to 2023. In 2023, $19,125 was paid across 6 transactions to 4 doctors.
The most common payment nature for LOVENOX is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($92,266, 58.5% of total).
LOVENOX is associated with 4 research studies, including "Effectiveness and Costs of LOVENOX? for Preventing Ischemic Complications among Patients with Unstable Angina and non-ST-segment elevation Myocardial Infarction in the United States" ($4,821).